{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:21:41Z","timestamp":1769242901147,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ophtha.2016.09.038","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T12:03:41Z","timestamp":1479211421000},"page":"245-256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["SCORE2 Report 2"],"prefix":"10.1016","volume":"124","author":[{"given":"Ingrid U.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"VanVeldhuisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1304-4101","authenticated-orcid":false,"given":"Michael S.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Blodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal L.","family":"Oden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin U.","family":"Dugel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2016.09.038_bib1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","article-title":"Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study","volume":"114","author":"Mitchell","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib2","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2016.09.038_bib3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.038_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/archopht.1993.01090080083022","article-title":"Baseline and early natural history report. The Central Vein Occlusion Study","volume":"111","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib5","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0161-6420(95)30848-2","article-title":"A\u00a0randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report","volume":"102","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.038_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archopht.1997.01100150488006","article-title":"Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group","volume":"115","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0161-6420(95)30849-4","article-title":"Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M Report","volume":"102","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.038_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00006982-200603000-00008","article-title":"Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases","volume":"26","author":"Opremcak","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.09.038_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/archopht.120.4.495","article-title":"Lamina puncture: pars plana optic disc surgery for central retinal vein occlusion","volume":"120","author":"Lit","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib10","first-page":"219","article-title":"Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion","volume":"99","author":"Elman","year":"2001","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.ophtha.2016.09.038_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0002-9394(02)01637-9","article-title":"Treatment of central retinal vein occlusion by vitrectomy with lysis of vitreopapillary and epipapillary adhesions, subretinal peripapillary tissue plasminogen activator injection, and photocoagulation","volume":"134","author":"Lam","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00006982-200507000-00014","article-title":"Retinal endovascular surgery for central retinal vein occlusion: initial experience of four surgeons","volume":"25","author":"Bynoe","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.09.038_bib13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9394(98)00156-1","article-title":"Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors","volume":"126","author":"McAllister","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00006982-200406000-00002","article-title":"Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases","volume":"24","author":"Mandelcorn","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.09.038_bib15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00006982-200603000-00005","article-title":"Intravitreal bevacizumab (avastin) treatment of macular edema in central retinal vein occlusion: a short-term study","volume":"26","author":"Iturralde","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.09.038_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0002-9394(14)75791-5","article-title":"A\u00a0randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin","volume":"118","author":"Glacet-Bernard","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/archophthalmol.2009.234","article-title":"SCORE Study Report 5. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion","volume":"127","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.038_bib19","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular Endothelial Growth Factor Trap-Eye for macular edema secondary to central retinal vein occlusion. Six-month results of the phase 3 COPERNICUS Study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.038_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase 3 GALILEO Study","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib21","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/IAE.0b013e3181cea68d","article-title":"Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion. Results of the Pan American Collaborative Retina Study Group at 24 months","volume":"30","author":"Wu","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.09.038_bib22","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1755-3768.2009.01758.x","article-title":"Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin)","volume":"88","author":"Algvere","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10792-008-9282-7","article-title":"Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results","volume":"30","author":"Beutel","year":"2010","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/IAE.0b013e318188501f","article-title":"Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion","volume":"28","author":"Gregori","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.09.038_bib25","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/IAE.0b013e3180ed458d","article-title":"Intravitreal bevacizumab injections for treatment of central retinal vein occlusion. Six-month results of a prospective trial","volume":"27","author":"Priglinger","year":"2007","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.09.038_bib26","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1136\/bjo.2009.173732","article-title":"Results of bevacizumab as the primary treatment for retinal vein occlusions","volume":"94","author":"Figueroa","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00417-009-1167-6","article-title":"Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion","volume":"248","author":"Ach","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib28","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00417-009-1151-1","article-title":"Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion","volume":"247","author":"Hoeh","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/bjo.2008.141085","article-title":"Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial","volume":"93","author":"Prager","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","article-title":"Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study","volume":"92","author":"Kriechbaum","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib31","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.09.038_bib32","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.09.038_bib33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","article-title":"Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): a European label study","volume":"169","author":"Hoerauf","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"13","key":"10.1016\/j.ophtha.2016.09.038_bib34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ophtha.2016.09.038_bib35","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/bjophthalmol-2011-300654","article-title":"Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug","volume":"96","author":"Stewart","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib36","series-title":"Medicare payments for drugs used to treat wet age-related macular degeneration","author":"Department of Health and Human Services, Office of Inspector General","year":"2012"},{"key":"10.1016\/j.ophtha.2016.09.038_bib37","series-title":"Red Book Online [database online]","year":"2016"},{"issue":"11","key":"10.1016\/j.ophtha.2016.09.038_bib38","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1001\/archopht.116.11.1496","article-title":"Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ)","volume":"116","author":"Mangione","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib39","unstructured":"Protocol for the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2), Version 3.0. Bethesda, MD: National Eye Institute. NTIS order numbers PB2016\u2013103333 and PB2016-103334 (Appendices II-IV) 2016."},{"issue":"3","key":"10.1016\/j.ophtha.2016.09.038_bib40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0197-2456(00)00057-X","article-title":"Computations for group sequential boundaries using the Lan-DeMets spending function method","volume":"21","author":"Reboussin","year":"2000","journal-title":"Control Clin Trials"},{"issue":"1","key":"10.1016\/j.ophtha.2016.09.038_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/(SICI)1097-0258(19980115)17:1<89::AID-SIM730>3.0.CO;2-D","article-title":"Modifying the design of ongoing trials without unblinding","volume":"17","author":"Gould","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ophtha.2016.09.038_bib42","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A\u00a0sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"10.1016\/j.ophtha.2016.09.038_bib43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archopht.1996.01100130537006","article-title":"Risk factors for central retinal vein occlusion","volume":"114","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.09.038_bib44","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.106.613828","article-title":"Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study","volume":"113","author":"Fox","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ophtha.2016.09.038_bib45","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2016.09.038_bib46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.publhealth.27.021405.102132","article-title":"Hypertension: trends in prevalence, incidence, and control","volume":"27","author":"Hajjar","year":"2006","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.ophtha.2016.09.038_bib47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.HYP.0000142248.54761.56","article-title":"The burden of adult hypertension in the United States 1999 to 2000: a rising tide","volume":"44","author":"Fields","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ophtha.2016.09.038_bib48","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/archophthalmol.2012.2728","article-title":"Baseline characteristics and response to treatment of participants with hemiretinal compared to branch retinal or central retinal vein occlusion in the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study: SCORE Study Report 14","volume":"130","author":"Scott","year":"2012","journal-title":"Arch Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016309022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016309022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T14:24:00Z","timestamp":1536243840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016309022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0161642016309022"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.038","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SCORE2 Report 2","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}